Navigation Links
Anthera's Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
Date:5/6/2009

ty, non-fatal stroke, non-fatal myocardial infarction, unstable angina, and a subset of revascularization following the initial event. During the course of the study, patients received therapeutic standard of care in addition to high dose Lipitor (atorvastatin).

In previous clinical trials, varespladib, a potent and highly selective inhibitor of secretory phospholipase A2 (sPLA2), has demonstrated marked improvements in independent markers of cardiovascular risk including, a near complete suppression of sPLA2 activity and mass, clinically meaningful and statistically significant reduction in LDL cholesterol, and a reduction in C-reactive protein.

About Acute Coronary Syndrome

Acute coronary syndrome is a heart condition characterized by chest pain occurring at rest or upon minimal exertion. This condition is also referred to as unstable angina. If the chest pain is associated with heart muscle damage and heart tracing abnormalities, it is typically classified as a heart attack or myocardial infarction.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a privately-held company committed to developing and commercializing clinical pharmaceutical products that address unmet medical needs of patients with life-threatening, chronic and acute inflammatory diseases and autoimmune disorders. The Company has acquired from Eli Lilly and Company and Shionogi & Co.┬┐ Ltd. worldwide rights (excluding Japan) to a series of clinical and pre-clinical compounds that inhibit the enzymatic activity of members of the phospholipase (PLA2) family - a group of enzymes responsible for the release of arachidonic acid and subsequent production of leukotrienes┬┐ prostacyclins and other mediators of inflammation. These highly potent compounds inhibit novel┬┐ upstream steps in the inflammation cascade and have the potential to address a variety of diseases. For more information, please visit

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
2. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
3. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
4. Schering-Ploughs Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study
5. Isolagen, Inc. Reports Positive Top-line Results from Phase II/III Study of Isolagen Therapy(TM) to Treat Moderate to Severe Acne Scars: Study Meets All Primary Efficacy Endpoints and is Statistically Significant
6. Alexzas AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial
7. TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia
8. Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinsons Disease
9. NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect
10. Alexzas AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients
11. Teliks Proteasome Inhibitor Program Meets a Preclinical Development Milestone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 The Cadence Fitness & Health ... by the Medical Fitness Association, a non-profit organization assisting ... full potential. The Cadence Fitness & Health Center is ... and second in the Chicagoland area. "The ...
(Date:1/15/2014)...  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") ... its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), for ... Solta Medical, Inc. (NASDAQ: SLTM ) ("Solta") ...
(Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly ... and painless for patients to self-inject prescription drugs in the ... including cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... grow to $220B by 2018, according to analysts.   Many of ...
Breaking Medicine Technology:Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2
(Date:7/9/2014)... A retrospective study conducted by researchers at Tufts University ... adults with intellectual and developmental disabilities, the likelihood of ... dental care increased. The findings, published in the July/August ... help improve interventions designed to address the oral health ... reviewed the dental records of 107 patients at one ...
(Date:7/9/2014)... , , , , , ... , , , , ... the microphone is 50m downrange from the firer and approximately 30cm from the bullet... , , ... , , , , , ... , , , , , , University ...
(Date:7/9/2014)... of Medicine of the University of Southern California ... component of the immune system are completely resistant ... The discovery suggests that blocking this immune system ... and hyper-inflammatory diseases such as rheumatoid arthritis and ... online on June 23 in The Journal ...
(Date:7/8/2014)... The Department of Defense,s Defense Advanced Research Projects ... up to $2.5 million to develop an implantable ... stimulate neurons within the brain to help restore ... research builds on the understanding that memory is ... of the brain encode information, store it and ...
(Date:7/8/2014)... In a study published yesterday in the scientific ... Jolla Institute (LJI) led by Pandurangan Vijayanand, Ph.D. identify new ... affects over 200 million people world wide. , An ... divided into small sections or ,neighborhoods., Scientists can determine ... for gene production, by looking for a marker on the ...
Breaking Medicine News(10 mins):Health News:Adults with special needs see gains, challenges with long term oral care 2Health News:Adults with special needs see gains, challenges with long term oral care 3Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 3Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 4Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 5Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 6Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 7Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 2Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 3Health News:LJI develops new approach to identify genes poised to respond in asthma patients 2
... TORRANCE, Calif., April 27 According to new ... , supplements of Lactobacillus casei strain Shirota may ... fatigue syndrome (CFS). Thirty-nine patients with CFS ... Shirota or placebo for two months. Compared ...
... Services Department declares a Public Health EmergencyHARRISBURG, Pa., April ... working with federal officials to contain the impact of ... in the declaration of a national public health emergency ... to educate the public and health care providers of ...
... toxins in the products we use for lifestyle convenience, ... toxic load on our bodies contributing to chronic illnesses, ... awareness of our environmental exposures, Metametrix Clinical Laboratory ( ... release of three new testing profiles in the Toxic ...
... 100 Exhibits, Forums on Health Care and Financial Security, ... Top Musicians***LOS LOBOS TO HEADLINE ENTERTAINMENT***SAN ANTONIO, April 27 ... for people age 50+, today announced it will bring ... San Antonio on May 15-16. The two-day, cross-generational ...
... screen at 40, but yearly PSA may not be necessary, ... guidelines on prostate cancer screening suggest that annual PSA blood ... same guidelines call for a "baseline" PSA test at the ... (PSA) test to detect early signs of prostate cancer should ...
... WHAT: , Media may now register to attend ... Symposium of the Cardiovascular Research Foundation. TCT gathers ... world to present and discuss the latest developments ... medicine. Now in its 21st year, TCT brings ...
Cached Medicine News:Health News:New Study Shows Supplementing With Probiotics May Ease Anxiety 2Health News:Pennsylvania Working Closely With Federal Partners to Contain Impact of Swine Flu 2Health News:Pennsylvania Working Closely With Federal Partners to Contain Impact of Swine Flu 3Health News:Metametrix Announces New Toxic Effects Profiles to Help Combat Growing Concerns About Toxicity and Health 2Health News:AARP to Host Cross-Generational 'Life Festival' in San Antonio May 15-16 2Health News:AARP to Host Cross-Generational 'Life Festival' in San Antonio May 15-16 3Health News:Experts Back Away From Annual PSA Test 2Health News:Experts Back Away From Annual PSA Test 3Health News:Media registration now open for TCT 2009 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: